Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for FB102 (Anti-CD122 Antibody) in Alopecia Areata. The expected timing is based on the latest available company guidance and may change.
11/14/25:- Ph1b alopecia areata trial enrolling; data from the study expected in 2026. 03/31/26:- Alopecia areata Phase 1b data readout still expected in 2026; timing guidance unchanged. 05/11/26:- Alopecia areata Ph1b data readout reiterated for 2026; no timing change announced.
Verification
Confirm timing and program details against the company announcement or filing.